Table 1.
Clinicopathological role of SHP-1 in tumors.
| Tumor Type | Reported Findings | Predicted Function | Refs |
|---|---|---|---|
| Acute myeloid leukemia | SHP-1 expression was negatively correlated with the overall survival of leukemia patients. | Oncogenic | [39] |
| Breast cancer | SHP-1 expression is inversely correlated with pSTAT3 and positively correlated with recurrence-free survival in patients. | Tumor suppressive | [33] |
| According to the TCGA database, high expression of SHP-1 was associated with better overall survival. | Tumor suppressive | [34] | |
| Higher SHP-1 expression associated with better overall survival. | Tumor suppressive | [35] | |
| Colorectal cancer | The survival time of patients with high SHP-1 expression is shorter than those of patients with low SHP-1 expression. | Oncogenic | [40] |
| Esophageal squamous cell carcinoma | Negative correlation with the tumor-node metastasis staging system, pathological differentiation, and lymph node metastasis: The downregulation and hypermethylation of SHP-1 are associated with poor survival. | Tumor suppressive | [20] |
| Glioblastoma | Upregulation of SHP-1 in GBM patients according to TCGA analysis. High expression of SHP-1 was associated with advanced grade and poor overall survival of glioma. |
Oncogenic | [41] |
| Hepatocellular carcinoma | Downregulation of SHP-1 in hepatocellular carcinoma (HCC) is negatively correlated with tumor growth and overall survival in patients with HCC and hepatitis B virus infection. | Tumor suppressive | [36] |
| Prostate cancer | A decreased SHP-1 expression is associated with higher proliferation rates and increased risk of recurrence or progression-free survival after radical prostatectomy for localized prostate cancer. | Tumor suppressive | [37] |